MedTrace Logo

Gut Microbiome and Treatment for Gynecological Cancer Patients Receiving Immunotherapy

NCT04957511 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 30

Last updated 2025-01-29

No results posted yet for this study

Summary

30 participants with advanced or recurrent gynecological cancer from are enrolled for this study. Eligible participants then provide fecal specimen, blood, vaginal swab, oral mucosal swab and receive food dietary recommendation. Additional samples are collected for results analysis.

Conditions

  • Gynecologic Cancer
  • Immunotherapy
  • Gut Microbiome

Sponsors & Collaborators

  • AdventHealth

    collaborator OTHER

  • Viome

    lead INDUSTRY

Principal Investigators

  • Momchilo Vuyisich, PhD · Viome Life Sciences

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-06-29
Primary Completion
2026-06-30
Completion
2026-06-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04957511 on ClinicalTrials.gov